Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy

European Journal of Pharmacology

Volumn 628, Issue 1-3, 2010, Pages 164-170

  Chatzikyriakou, Sofia V ^a   Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Stakos, Dimitrios ^a   Thomaidi, Adina ^a   Mitrousi, Konstantina ^a   Boudoulas, Harisios ^b  

^a Department   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Angiotensin converting enzyme inhibitor; Chronic heart failure; Collagen metabolism; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLLAGEN TYPE 1; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

AGED; ARTICLE; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CHRONIC DISEASE; COLLAGEN TYPE I; FEMALE; HEART FAILURE; HUMANS; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 73649129162     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.047     Document Type: Article

References (26)

1. Cheitlin M.D., Alpert J.S., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davidson T.W., Davis J.L., Douglas P.S., and Gillam L.D. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation 95 (1997) 1686-1744
2. Cleland J.G., Cohen-Solal A., Aguilar J.C., Dietz R., Eastaugh J., Follath F., Freemantle N., Gavazzi A., van Gilst W.H., Hobbs F.D., Korewicki J., Madeira H.C., Preda I., Swedberg K., Widimsky J., and IMPROVEMENT of Heart Failure Programme Committees and Investigators. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360 (2002) 1631-1639
3. Dickerson J.E., Hingorani A.D., Ashby M.J., Palmer C.R., and Brown M.J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353 (1999) 2008-2013
4. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Strömberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Tendera M., Auricchio A., Bax J., Böhm M., Corrà U., della Bella P., Elliott P.M., Follath F., Gheorghiade M., Hasin Y., Hernborg A., Jaarsma T., Komajda M., Kornowski R., Piepoli M., Prendergast B., Tavazzi L., Vachiery J.L., Verheugt F.W., Zamorano J.L., and Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail. 10 (2008) 933-989
5. Feigenbaum H., Armstrong W.F., and Ryan T. Feigenbaum's Echocardiography. Sixth ed (2005), Lippincott Williams & Wilkins, Philadelphia 138-179
6. Fleming I. Signaling by the angiotensin-converting enzyme. Circ. Res. 98 (2006) 887-896
7. Follath F. Beta-blockade today: the gap between evidence and practice. Eur. Heart J. Suppl. 8 (2006) C28-C34
8. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. J.A.M.A. 18 (1995) 1450-1455
9. Gonzalez A., Lopez B., Querejeta R., and Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. J. Mol. Cell Cardiol. 34 (2002) 1585-1593
10. Hoite B.D. Matrix metalloproteinases and atrial structural remodelling. J. Am. Coll. Cardiol. 42 (2003) 345-347
11. Jan Danser A.H., Batenburg W.W., Van den Meiracker A.H., and Danilov S.M. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?. Pharmacol. Therap. 113 (2007) 607-618
12. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix. When is enough enough?. Circulation 108 (2003) 1395-1403
13. Kazi D., and Deswal A. Role and optimal dosing of angiotensin-converting enzyme inhibitors and in heart failure. Cardiol. Clin. 26 (2008) 1-14
14. Kitahara T., Takeishi Y., Arimoto T., Niizeki T., Koyama Y., Sasaki T., Suzuki S., Nozaki N., Hirono O., Nitobe J., Watanabe T., and Kubota I. Serum carboxy terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ. J. 71 (2007) 929-935
15. Klappacher G., Franzen P., Haab D., Mehrabi M., Binder M., Plesc K., Pacher R., Grimm M., Pribill I., Eichler H.G., and Glogar H.D. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am. J. Cardiol. 75 (1995) 913-918
16. Komajda M., Follath F., Swedberg K., Cleland J., Aguilar J.C., Cohen-Solal A., Dietz R., Gavazzi A., Van Gilst W.H., Hobbs R., Korewicki J., Madeira H.C., Moiseyev V.S., Preda I., Widimsky J., Freemantle N., Eastaugh J., Mason J., and Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 24 (2003) 464-474
17. Landmesser U., Wollert K.C., and Drexler H. Potential novel pharmacological therapies for myocardial remodeling. Cardiovasc. Res. 81 (2009) 519-527
18. Roig E., Perez- Villa F., Morales M., Jimenez W., Orus J., Heras M., and Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart J. 21 (2000) 53-57
19. Shekelle P.G., Rich M.W., Morton S.C., Atkinson C.S., Tu W., Maglione M., Rhodes S., Barett M., Fonarow G.C., Greenberg B., Heidenreich P.A., Knabel T., Konstam M.A., Steimle A., and Warner-Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major clinical trials. J. Am. Coll. Cardiol. 41 (2003) 1529-1538
20. Struthers A.D., Anderson G., MacFadyen R.J., Fraser C., and MacDonald T.M. Non-adherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activity. Congest. Heart Fail. 7 (2001) 43-46
21. Van de Wal R.M.A., Plokker H.W.M., Lok D.J.A., Boomsma F., Van der Horst F.A.L., Van Veldhuisen D.J., Van Gilst W.H., and Voors A.A. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int. J. Cardiol. 106 (2006) 367-372
22. Weber K.T. Monitoring tissue repair and fibrosis from a distance. Circulation 96 (1997) 2488-2892
23. Yamamoto K., Masuyama T., Sakata Y., Nishikawa N., Mano T., Yoshida J., Miwa T., Sugawara M., Yamaguchi Y., Ookawara T., Suzuki K., and Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc. Res. 55 (2002) 76-82
24. Zannad F., and Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Failure Reviews 10 (2005) 71-78
25. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000) 2700-2706
26. Zannad F., Dousset B., and Alla F. Treatment of congestive heart failure. Interfering the aldosterone cardiac extracellular matrix relationship. Hypertension 38 (2001) 1227-1232